How to cite this article: Kern W, Bacher U, Schnittger S, Alpermann T, Haferlach C, Haferlach T. Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms. Cytometry Part B 2012; 84B: 194–197.
Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms†
Article first published online: 2 JAN 2013
Copyright © 2012 International Clinical Cytometry Society
Cytometry Part B: Clinical Cytometry
Volume 84B, Issue 3, pages 194–197, May 2013
How to Cite
Kern, W., Bacher, U., Schnittger, S., Alpermann, T., Haferlach, C. and Haferlach, T. (2013), Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms. Cytometry, 84B: 194–197. doi: 10.1002/cyto.b.21068
- Issue published online: 19 APR 2013
- Article first published online: 2 JAN 2013
- Manuscript Accepted: 30 NOV 2012
- Manuscript Revised: 17 NOV 2012
- Manuscript Received: 20 MAR 2012
- myelodysplastic/myeloproliferative neoplasm (MDS/MPN);
- MDS-related immunophenotypes;
- multiparameter flow cytometry;
Within the myelodysplastic/myeloproliferative neoplasm (MDS/MPN) category of the WHO (2008), only chronic myelomonocytic leukemia was so far evaluated by multiparameter flow cytometry (MFC).
To investigate the potential of MFC for MDS/MPNs, unclassifiable (MDS/MPNu), and refractory anemia associated with ring sideroblasts and marked thrombocytosis (RARS-T), we studied 91 patients with these entities (60 males/31 females; 35.3–87.4 years) for MDS-related aberrant immunophenotypes (≥2 different cell lineages with ≥3 aberrantly expressed antigens). Data were correlated with cytomorphology and cytogenetics.
MFC identified MDS-related immunophenotypes in 54/91 (59.3%) of patients. Patients with or without MDS-related immunophenotype did not differ significantly by demographic characteristics, blood values, or median overall survival. MDS-related immunophenotype cases showed a higher number of aberrantly expressed antigens (mean ± SD, 4.9 ± 2.4 vs. 2.0 ± 1.4; P < 0.001). Aberrant karyotypes showed a similar frequency in patients with and without MDS-related immunophenotype (11/54; 20.4% vs. 7/37; 18.9%; P = n.s.).
MDS-related immunophenotype are present in more than half of patients with MDS/MPNu and RARS-T. MFC therefore may be helpful to separate cases into more “MDS-like” or “MPN-like” subgroups. © 2012 International Clinical Cytometry Society